A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab vs Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lympho

A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab vs Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lympho

Trial Category:
Lymphoma
Phase
III
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Southeast Nebraska Cancer Center, Lincoln, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members